David Arnott
Overview
Explore the profile of David Arnott including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
56
Citations
3266
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Bashore C, Prakash S, Johnson M, Conrad R, Kekessie I, Scales S, et al.
Nat Chem Biol
. 2022 Dec;
19(1):55-63.
PMID: 36577875
Engineered destruction of target proteins by recruitment to the cell's degradation machinery has emerged as a promising strategy in drug discovery. The majority of molecules that facilitate targeted degradation do...
2.
Barreira da Silva R, Leitao R, Pechuan-Jorge X, Werneke S, Oeh J, Javinal V, et al.
Nat Immunol
. 2022 Mar;
23(4):568-580.
PMID: 35314846
Tumor-associated macrophages are composed of distinct populations arising from monocytes or tissue macrophages, with a poorly understood link to disease pathogenesis. Here, we demonstrate that mouse monocyte migration was supported...
3.
4.
Pham V, Pitti R, Tindell C, Cheung T, Masselot A, Stephan J, et al.
J Proteome Res
. 2020 Mar;
19(4):1533-1547.
PMID: 32159963
Acquisition of drug resistance remains a chief impediment to successful cancer therapy, and we previously described a transient drug-tolerant cancer cell population (DTPs) whose survival is in part dependent on...
5.
de Almeida Nagata D, Chiang E, Jhunjhunwala S, Caplazi P, Arumugam V, Modrusan Z, et al.
Cell Rep
. 2019 Apr;
27(1):269-281.e4.
PMID: 30943407
Myeloid-derived suppressor cells (MDSCs) are found in most cancer malignancies and support tumorigenesis by suppressing immunity and promoting tumor growth. Here we identify the bromodomain (BRD) of CBP/EP300 as a...
6.
Raisner R, Kharbanda S, Jin L, Jeng E, Chan E, Merchant M, et al.
Cell Rep
. 2018 Aug;
24(7):1722-1729.
PMID: 30110629
Acetylation of histone H3 at lysine 27 is a well-defined marker of enhancer activity. However, the functional impact of this modification at enhancers is poorly understood. Here, we use a...
7.
Arenzana T, Lianoglou S, Seki A, Eidenschenk C, Cheung T, Seshasayee D, et al.
Sci Immunol
. 2018 Apr;
3(22).
PMID: 29678836
Loss of function of the nuclear deubiquitinating enzyme BRCA1-associated protein-1 (BAP1) is associated with a wide spectrum of cancers. We report that tamoxifen-induced BAP1 deletion in adult mice resulted in...
8.
Leadem B, Kagiampakis I, Wilson C, Cheung T, Arnott D, Trojer P, et al.
Cancer Res
. 2017 Dec;
78(5):1127-1139.
PMID: 29282222
The H3K4 demethylase is amplified and overexpressed in luminal breast cancer, suggesting it might constitute a potential cancer therapy target. Here, we characterize, in breast cancer cells, the molecular effects...
9.
Viotti M, Wilson C, McCleland M, Koeppen H, Haley B, Jhunjhunwala S, et al.
J Cell Biol
. 2017 Dec;
217(2):763-777.
PMID: 29229751
Epithelial-to-mesenchymal transition is implicated in metastasis, where carcinoma cells lose sessile epithelial traits and acquire mesenchymal migratory potential. The mesenchymal state is also associated with cancer stem cells and resistance...
10.
Cuellar T, Herzner A, Zhang X, Goyal Y, Watanabe C, Friedman B, et al.
J Cell Biol
. 2017 Sep;
216(11):3535-3549.
PMID: 28887438
A propensity for rewiring genetic and epigenetic regulatory networks, thus enabling sustained cell proliferation, suppression of apoptosis, and the ability to evade the immune system, is vital to cancer cell...